Mettler-Toledo International Inc (MTD) carries a ŷRobot AI score of 54 out of 100. The model's fair value estimate is $1,533.66, 0.4% above the last close of $1,527.77. The chart signal reads Sell.
| Metric | MTD |
|---|---|
| AI score | 54 / 100 |
| Chart signal | Sell |
| Fair value estimate | $1,533.66 |
| Upside to fair value | 0.4% |
| Previous close | $1,527.77 |
| P/E | 34.60 |
| Price / sales | 7.18 |
| Market cap | $30.89B |
| EPS | 44.43 |
| Revenue growth | 1.0% |
| 1-year price change | 0.0% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
As of Oct 8, 2026, ŷRobot's fair-value model estimates Mettler-Toledo International Inc (MTD) at $1533.66 against a last close of $1527.77, implying 0.4% upside to the model's estimate.
The chart-signal model classifies MTD as Neutral as of Oct 8, 2026, with a signal score of -0.11 on a -1 to 1 scale.
MTD scores 54 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Oct 8, 2026.
MTD trades at 34.6 times earnings and 7.2 times sales as of Oct 8, 2026.
ŷRobot's seasonal forecast curve for MTD reads +0.5% at 30 days, +5.1% at 90 days, and +0.0% at one year as of Oct 8, 2026. Seasonal tendencies are historical patterns, not predictions.
Mettler-Toledo International Inc's revenue growth is +1.0% and free-cash-flow growth is -3.1% on the latest reported figures.
MTD chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.